Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease. (2014). Farmeconomia. Health Economics and Therapeutic Pathways, 15(3). https://doi.org/10.7175/fe.v15i3.938